Biovail CEO Joins From MDS Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Biovail CEO John Squires, PhD, is joining the company after six years at MDS Pharma
You may also be interested in...
Biovail Exits U.S. Primary Care Market; Narrows Focus To Specialty Sales
In an attempt to boost profitability, Biovail will divest its Teveten franchise to Kos, which will also gain distribution rights for Cardizem LA. The $104 mil. deal also includes an R&D collaboration for three products in Biovail's cardiovascular product pipeline.
Biovail Exits U.S. Primary Care Market; Narrows Focus To Specialty Sales
In an attempt to boost profitability, Biovail will divest its Teveten franchise to Kos, which will also gain distribution rights for Cardizem LA. The $104 mil. deal also includes an R&D collaboration for three products in Biovail's cardiovascular product pipeline.
Biovail Narrows Revenue Guidance; Projected Earnings Remains Unchanged
The company revises its revenue guidance to $820-$920 mil. from $800-$940 mil. Estimate reflects stronger than expected Wellbutrin XL growth as well as lagging Cardizem LA, Teveten and Zovirax sales.